These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32835332)

  • 1. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.
    Tonn T; Corman VM; Johnsen M; Richter A; Rodionov RN; Drosten C; Bornstein SR
    Lancet Microbe; 2020 Jun; 1(2):e63. PubMed ID: 32835332
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
    Nguyen D; Simmonds P; Steenhuis M; Wouters E; Desmecht D; Garigliany M; Romano M; Barbezange C; Maes P; Van Holm B; Mendoza J; Oyonarte S; Fomsgaard A; Lassaunière R; Zusinaite E; Resman Rus K; Avšič-Županc T; Reimerink JH; Brouwer F; Hoogerwerf M; Reusken CB; Grodeland G; Le Cam S; Gallian P; Amroun A; Brisbarre N; Martinaud C; Leparc Goffart I; Schrezenmeier H; Feys HB; van der Schoot CE; Harvala H
    Euro Surveill; 2021 Jul; 26(27):. PubMed ID: 34240697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2.
    Müller K; Girl P; Giebl A; von Buttlar H; Dobler G; Bugert JJ; Gruetzner S; Wölfel R
    J Clin Virol; 2021 Sep; 142():104912. PubMed ID: 34298379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 5. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
    Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C
    Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.
    Bellusci L; Golding H; Khurana S
    J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36821375
    [No Abstract]   [Full Text] [Related]  

  • 8. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [COVID-19: Still a place for the convalescent plasma? Focus on the immunocompromised patients].
    Richier Q; Hueso T; Tiberghien P; Lacombe K
    Rev Med Interne; 2023 Sep; 44(9):467-471. PubMed ID: 37689526
    [No Abstract]   [Full Text] [Related]  

  • 10. How should we use convalescent plasma therapies for the management of COVID-19?
    Wood EM; Estcourt LJ; McQuilten ZK
    Blood; 2021 Mar; 137(12):1573-1581. PubMed ID: 33202419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.
    Pang NY; Pang AS; Chow VT; Wang DY
    Mil Med Res; 2021 Aug; 8(1):47. PubMed ID: 34465396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.
    Diorio C; Anderson EM; McNerney KO; Goodwin EC; Chase JC; Bolton MJ; Arevalo CP; Weirick ME; Gouma S; Vella LA; Henrickson SE; Chiotos K; Fitzgerald JC; Kilbaugh TJ; John ARO; Blatz AM; Lambert MP; Sullivan KE; Tartaglione MR; Zambrano D; Martin M; Lee JH; Young P; Friedman D; Sesok-Pizzini DA; Hensley SE; Behrens EM; Bassiri H; Teachey DT
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28693. PubMed ID: 32885904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of anti-SARS-COV2 spike protein IgG and IgA antibodies at 4°C: Implications for convalescent plasma stability.
    Focosi D; Moscato G; Pistello M; Maggi F
    Transfus Med; 2021 Jun; 31(3):221-222. PubMed ID: 33899263
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors.
    Franchini M; Glingani C; Liumbruno GM; Mengoli C
    Transfus Apher Sci; 2021 Dec; 60(6):103216. PubMed ID: 34315677
    [No Abstract]   [Full Text] [Related]  

  • 16. Rethinking the role of COVID-19 convalescent plasma in the critically ill.
    Casadevall A; Pirofski LA
    Transfus Apher Sci; 2023 Feb; 62(1):103521. PubMed ID: 35941021
    [No Abstract]   [Full Text] [Related]  

  • 17. Convalescent plasma for SARS-CoV-2 infection: win or learn.
    Contreras-Barbeta E; Millan A; Rello J
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34531275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy.
    Focosi D; Franchini M; Casadevall A
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.
    Razumikhin M; Smolyanova T; Nikolaeva A; Orlova E; Ivanov A; Belyakova O; Vyaznikova T; Selezneva N; Perevozchikov A; Sokolova A; Zubkova N; Efimova I; Dolzhikova I; Logunov D; Sakanjan E
    Immunotherapy; 2022 Oct; 14(14):1133-1147. PubMed ID: 35892311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.